The ristocetin-Willebrand factor assay showed decreased levels (0 to 41%) in patients with von Willebrand's disease compared to all other subjects (79 to 202%).
Observational
Can the ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation accurately identify patients with von Willebrand's disease?
The ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation are useful diagnostic and screening tools for von Willebrand's disease.
Normal subjects, patients with various bleeding disorders, and patients with von Willebrand's disease were studied. All patients with von Willebrand's disease had decreased levels of ristocetin-Willebrand factor (range, 0 to 41%) as compared with all other subjects (range, 79 to 202%). Ristocetin-induced platelet aggregation of platelet-rich plasma was abnormal in all patients with von Willebrand's disease tested, and it was possible to correct this abnormal response by addition of normal platelet-poor plasma. Abnormal ristocetin-induced platelet aggregation was seen in patients with intrinsic platelet disorders or, on some occasions, in normal patients who had ingested aspirin. Ristocetin-induced platelet aggregation is not diagnostic, but it may be useful as a simple screening test for patients with possible von Willebrand's disease. In conjunction with other tests, the assay for ristocetin-Willebrand factor will be useful in diagnosis and evaluation of these patients.
Olson et al. (Sun,) conducted a observational in von Willebrand's disease. Ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation vs. Normal subjects and patients with other bleeding disorders was evaluated on Ristocetin-Willebrand factor levels. The ristocetin-Willebrand factor assay showed decreased levels (0 to 41%) in patients with von Willebrand's disease compared to all other subjects (79 to 202%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: